Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of asunercept plus standard of care in hospitalized patients with moderate to severe COVID-19
2021-006005-30Phase 3Terminated
- Sponsor
- Apogenix
- Start
- Jul 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Asunercept plus standard of care with Placebo plus standard of care (2 arms). Started Jul 2022; status: terminated.
02
Drugs
asunercept
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-006005-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006005-30.